Healthcare
Live Price
Offline$1.60
+0.00% today
1Y Change
-25.74%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NovaBridge Biosciences (NBP) is a Healthcare stock with a market cap of $1.87B and listed on NASDAQ. The stock last traded around $1.60 and down 25.7% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +75.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +75.3%, free cash flow +60.9% with operating margin 0.0% and ROIC -40.3%. Stock Foundry combines NBP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NBP
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NBP Max Drawdown
-77.59%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NBP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.5B
+1652.5% YoY
FY Net Income
$470.9M
+120.2% YoY
Free Cash Flow
$425.6M
+142.4% YoY
Revenue Growth
+0.0%
EPS Growth
+75.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 4M | -11M | 88M | 1.5B |
| Gross Profit | 0 | 4M | -249M | 42M | 1.5B |
| Operating Income | -375M | -511M | -366M | -2.1B | 156M |
| EBITDA | -373M | -344M | -51M | -2.1B | 168M |
| Net Income | -162M | -1.5B | -2.5B | -2.3B | 471M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 68M | 2.1B | 3.2B | 3.5B | 4.8B |
| Total Assets | 213M | 2.6B | 4.1B | 5.6B | 6.3B |
| Total Liabilities | 12M | 895M | 1.1B | 1.0B | 707M |
| Shareholder Equity | 201M | 1.7B | 3.0B | 4.6B | 5.6B |
| Total Debt | 4M | 134M | 38M | 112M | 14M |
| Net Debt | -64M | -2.0B | -3.2B | -3.4B | -4.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
434M
+144.6% YoY
Capital Expenditures
8M
+73.2% YoY
Free Cash Flow
426M
+142.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-7.5%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.